Genmab stock tumbles after J&J opts out of licensing deal
-- Shares of Genmab (NASDAQ:GMAB) fell sharply by 10% following news that Johnson & Johnson (NYSE:JNJ) (J&J) will not exercise its option for a worldwide license to...
-- Shares of Genmab (NASDAQ:GMAB) fell sharply by 10% following news that Johnson & Johnson (NYSE:JNJ) (J&J) will not exercise its option for a worldwide license to...
- Canada's main stock index was down on Monday, after continued uncertainty regarding U.S. and China tariffs. By 10:00 ET, the S&P/TSX 60 index had fallen by 13.6...
-- U.S. stocks fell Monday, continuing the previous week's selloff amid concerns that President Donald Trump’s tariff policies could hit U.S. economic activity. At...
-- Jefferies downgraded Sherwin-Williams Co (NYSE:SHW) to "Hold" from "Buy" also cutting its price target by 10% to $380 amid concerns over a weakening housing market...
(Reuters) - ArcelorMittal (NYSE:MT) on Monday announced a more than 270 million euro ($275.4 million) maintenance programme that would include the halt of activities at its plants...
-- Elon Musk’s increasing involvement in politics could be damaging Tesla’s already struggling electric vehicle sales, according to China’s Passenger Car Association...
(Reuters) -Assura said on Monday it would consider a 1.61 billion pound ($2.1 billion) offer from U.S. private equity group KKR and Stonepeak Partners, pushing shares of the...
-- AI-based commercial trucking insurance tech company, Nirvana Insurance, recently completed an $80 million Series C funding round. This latest round of funding has...
-- British insurance and asset management firm M&G announced on Monday that its private markets business has been granted regulatory approval for its inaugural...
-- Shares of Palantir Technologies Inc . (NASDAQ:PLTR) fell 6% early Monday, despite the company's upcoming inclusion in the S&P 100. The data analytics firm is set...